Catalyst Pharmaceuticals/$CPRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Ticker
$CPRX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
181
ISIN
US14888U1016
Website
CPRX Metrics
BasicAdvanced
$2.7B
13.89
$1.57
0.70
-
Price and volume
Market cap
$2.7B
Beta
0.7
52-week high
$26.58
52-week low
$14.97
Average daily volume
1.2M
Financial strength
Current ratio
6.142
Quick ratio
5.848
Long term debt to equity
0.338
Total debt to equity
0.389
Profitability
EBITDA (TTM)
269.169
Gross margin (TTM)
83.50%
Net profit margin (TTM)
36.91%
Operating margin (TTM)
43.27%
Effective tax rate (TTM)
23.64%
Revenue per employee (TTM)
$2,950,000
Management effectiveness
Return on assets (TTM)
18.59%
Return on equity (TTM)
29.11%
Valuation
Price to earnings (TTM)
13.886
Price to revenue (TTM)
4.873
Price to book
3.34
Price to tangible book (TTM)
4.11
Price to free cash flow (TTM)
9.737
Free cash flow yield (TTM)
10.27%
Free cash flow per share (TTM)
223.67%
Growth
Revenue change (TTM)
29.97%
Earnings per share change (TTM)
178.13%
3-year revenue growth (CAGR)
51.51%
3-year earnings per share growth (CAGR)
55.17%
10-year earnings per share growth (CAGR)
20.36%
What the Analysts think about CPRX
Analyst ratings (Buy, Hold, Sell) for Catalyst Pharmaceuticals stock.
Bulls say / Bears say
Catalyst Pharmaceuticals reported record first-quarter 2025 revenues of $141.4 million, a 43.6% year-over-year increase, driven by strong sales of FIRDAPSE® and AGAMREE® (GlobeNewswire).
The company has a robust financial position with cash and cash equivalents totaling $580.7 million as of March 31, 2025, providing ample resources for future growth initiatives (GlobeNewswire).
Analysts maintain a 'Strong Buy' consensus for CPRX stock, with a 12-month price target of $32.29, indicating a potential upside of approximately 38% from the current price (StockAnalysis).
Catalyst Pharmaceuticals' stock price has experienced volatility, with a recent close at $23.37, reflecting a 2.68% increase, but after-hours trading showed a decline of 1.63%, indicating potential investor uncertainty (MarketBeat).
The company's P/E ratio of 19.81 is higher than the industry average, suggesting that the stock may be overvalued relative to its earnings (MarketBeat).
Insider transactions show that shares worth $7.0 million were sold over the last three months, which could signal a lack of confidence among company executives (TipRanks).
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
CPRX Financial Performance
Revenues and expenses
CPRX Earnings Performance
Company profitability
CPRX News
AllArticlesVideos
Strong Inflows Make Catalyst Stock an Outlier
FXEmpire·3 weeks ago
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
GlobeNewsWire·4 weeks ago
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Catalyst Pharmaceuticals stock?
Catalyst Pharmaceuticals (CPRX) has a market cap of $2.7B as of June 30, 2025.
What is the P/E ratio for Catalyst Pharmaceuticals stock?
The price to earnings (P/E) ratio for Catalyst Pharmaceuticals (CPRX) stock is 13.89 as of June 30, 2025.
Does Catalyst Pharmaceuticals stock pay dividends?
No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Catalyst Pharmaceuticals dividend payment date?
Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.